Clovis Oncology, Inc.
CLVSQ Healthcare Biotechnology
Operating cash flow growth for five consecutive years.
Follow CLVSQ
Clovis Oncology, Inc. (CLVSQ) EV/Sales
As of 21 February 2023, Clovis Oncology, Inc. (CLVSQ) trades at a EV/Sales of 3.1×. Over the past ten years it has ranged from 0.0× (September 2017) to 72.8× (October 2017); the current reading is higher than 35% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | 5.3× | 12.58% |
| FY2020 | 4.7× | (29.17%) |
| FY2019 | 6.6× | (35.99%) |
| FY2018 | 10.4× | (79.61%) |
| FY2017 | 50.9× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2022 | 4.3× | (26.41%) |
| Jun 2022 | 5.8× | 6.43% |
| Mar 2022 | 5.5× | 3.04% |
| Dec 2021 | 5.3× | (14.88%) |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | −66.3× |
| LPCN Lipocine Inc. compare | −5.2× |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| RVLP RVL Pharmaceuticals PLC compare | 1.0× |
| CLVSQ Clovis Oncology, Inc. | 3.1× |
| CNSY Cerenome, Inc. compare | 3.3× |
| DARE Dare Bioscience, Inc. compare | 4.7× |
| TVRD Tvardi Therapeutics, Inc. compare | 4.8× |
| BCDA BioCardia, Inc. compare | 30.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)